Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gadoquatrane→

Gadoquatrane PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not verified
Molecular formula
Not verified
Molecular weight
Not verified g/mol
Drug class
Gadolinium-based MRI contrast agenttetrameric macrocyclic non-ionic gadolinium chelate
Mechanism of action
The intact tetrameric macrocyclic gadolinium complex is paramagnetic and shortens T1 relaxation times, increasing signal intensity in tissues where the contrast agent distributes. It is a diagnostic contrast chelate, not a therapeutic agent.
Indications / reported uses
  • MRI contrast enhancement for adults and paediatric patients with known or suspected abnormalities of the central nervous system and other body regions under the applicable product authorisation; confirm current country-specific label and approval status before assigning precise indications

Sources: US DailyMed — Gadoquatrane product information · NLM MeSH — Gadoquatrane · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Gadolinium-based MRI contrast agent; tetrameric macrocyclic non-ionic gadolinium chelate

Mechanism of action

The intact tetrameric macrocyclic gadolinium complex is paramagnetic and shortens T1 relaxation times, increasing signal intensity in tissues where the contrast agent distributes. It is a diagnostic contrast chelate, not a therapeutic agent.

General use cases

  • MRI contrast enhancement for adults and paediatric patients with known or suspected abnormalities of the central nervous system and other body regions under the applicable product authorisation; confirm current country-specific label and approval status before assigning precise indications

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Gadoquatrane PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gadoquatrane Permitted Daily Exposure (PDE) report (the Gadoquatrane PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gadoquatrane Occupational Exposure Limit (OEL) report (the Gadoquatrane OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.